Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | FLT4 | P35916 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL7815433 | 0.94 | PPARG (0.40) | TRPM8GABRA1GABRG2GABRB3GABRA5 | |
| Acetic Acid SCHEMBL7814729 | 0.93 | MMP13 (0.42) | TRPM8PDE4BPDE4DKDM4ELMNA | |
| Acetic Acid SCHEMBL7815908 | 0.92 | CAMK2D (0.39) | TRPM8CAMK2DLTB4RSRD5A2PDE4B | |
| Acetic Acid SCHEMBL7658238 | 0.92 | EGLN1 (0.40) | TRPM8CAMK2DLTB4RSRD5A2EGFR | |
| Acetic Acid SCHEMBL7657826 | 0.90 | CHEK1 (0.39) | TRPM8GABRA1GABRG2GABRB3GABRA5 | |
| Acetic Acid SCHEMBL7817644 | 0.90 | EGLN1 (0.40) | TRPM8CAMK2DLTB4RSRD5A2PDE4B | |
| Acetic Acid SCHEMBL7657890 | 0.90 | CHEK1 (0.39) | TRPM8CAMK2DLTB4RSRD5A2PDE4B | |
| Acetic Acid SCHEMBL7661589 | 0.88 | IP6K1 (0.42) | TRPM8CAMK2DLTB4RSRD5A2PDE4B | |
| Acetic Acid SCHEMBL7657949 | 0.88 | MC4R (0.38) | MAPTSRD5A2EGFRIGF1RFLT4 | |
| Acetic Acid SCHEMBL7664666 | 0.88 | MAOA (0.38) | MAPTSRD5A2EGFRIGF1RFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010025043-A1 | New pharmaceutical active compounds | ASTRA AKTIEBOLAG, A SWEDEN CORPORATION | 2001-09-27 | — | — | US | disclosed |
| US-6271231-B1 | Pharmaceutically active compounds | ASTRA AKTIEBOLAG (SE) | 2001-08-07 | — | — | US | disclosed |
| EP-0929551-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | Astra Aktiebolag (publ) (SE) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998013368-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | ASTRA AKTIEBOLAG (PUBL) (SE) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025043-A1 | New pharmaceutical active compounds | CSNK1A1, CSNK1G1, CSNK2A1 | TRPM8 1793/4885GABRA1 2832/4885GABRG2 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.